The Asia Pacific hospital acquired disease testing market is currently witnessing strong growth. Hospital-acquired diseases (HADs), or nosocomial infections, refer to the infections caused by exposure to viral, bacterial and fungal pathogens during hospital visits. Some of the commonly used techniques for testing HADs include the complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test and urinalysis, which are administered to diagnose catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI) and hospital-acquired pneumonia (HAP).
The rising prevalence of nosocomial infections in the Asia Pacific region is one of the key factors driving the market growth. Being a region majorly populated by developing economies, there is a dire lack of adequate sanitation and related provisions across the healthcare sector, especially in small-scale hospitals and clinics. Consequently, patients are increasingly being exposed to multidrug-resistant bacteria (MDRB) and viruses, which, in turn, is resulting in the growing demand for pathogen detection and other HAD testing procedures. In addition to this, the implementation of favorable government initiatives to promote public health and create awareness regarding the available treatment options for HADs, are contributing to the market growth significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of medical sciences, are anticipated to drive the market further. Looking forward, IMARC Group expects the market to witness robust growth during 2021-2026.?
IMARC Group provides an analysis of the key trends in each sub-segment of the Asia Pacific hospital acquired disease testing market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region and indication.
Breakup by Indication:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at